These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31267510)

  • 1. Monitoring testosterone replacement therapy with transdermal gel: when and how?
    Sansone A; Sansone M; Selleri R; Schiavo A; Gianfrilli D; Pozza C; Zitzmann M; Lenzi A; Romanelli F
    J Endocrinol Invest; 2019 Dec; 42(12):1491-1496. PubMed ID: 31267510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
    Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
    Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.
    Borst SE; Yarrow JF
    Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1035-42. PubMed ID: 25898953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
    Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N;
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
    Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications.
    Swerdloff RS; Pak Y; Wang C; Liu PY; Bhasin S; Gill TM; Matsumoto AM; Pahor M; Surampudi P; Snyder PJ
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3280-7. PubMed ID: 26120790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
    Dobs A; Norwood P; Potts S; Gould E; Chitra S
    J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
    Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
    Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New modalities of transdermal testosterone replacement.
    Basaria S; Dobs AS
    Treat Endocrinol; 2003; 2(1):1-9. PubMed ID: 15871550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.
    Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N
    Clin Endocrinol (Oxf); 2001 Jun; 54(6):739-50. PubMed ID: 11422108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of testosterone gel treatment on spermatogenesis in men with hypogonadism.
    George M; Yulia T; Svetlana K
    Gynecol Endocrinol; 2014 Oct; 30 Suppl 1():22-4. PubMed ID: 25200823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men.
    Singh AB; Norris K; Modi N; Sinha-Hikim I; Shen R; Davidson T; Bhasin S
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2437-45. PubMed ID: 11397836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.